Trial Profile
A PHASE 3, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SINGLE DOSE OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN JAPANESE SUBJECTS AGED 6 TO 64 YEARS WHO ARE CONSIDERED TO BE AT INCREASED RISK OF PNEUMOCOCCAL DISEASE AND WHO ARE NAIVE TO PNEUMOCOCCAL VACCINES
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
- 23 Sep 2021 Results assessing safety and immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) in Japanese individuals aged 6-64 years who were considered at risk of pneumococcal disease, published in the Vaccine.
- 22 Jan 2019 Status changed from recruiting to completed.
- 23 Aug 2018 Status changed from not yet recruiting to recruiting.